Memorial Hermann has been recognized for its overall performance in serving both individuals and the community. Photo via memorialhermann.org

Houston hospitals have been evaluated by a new ranking to determine the institutions that are doing their best to serve their patients and the community as a whole.

Brookline, Massachusetts-based think tank, The Lown Institute, has revealed its national rankings on its Lown Institute Hospitals Index — which evaluated hospitals based on civic leadership (based on inclusion and access), value of care, and patient outcomes (which evaluates safety and satisfaction).

"At a time when communities are relying on them like never before, hospitals must rethink what it means to be great," says Dr. Vikas Saini, president of the Lown Institute, in a news release. "COVID-19 highlights how hospitals are essential community partners for anyone in need. To be great, however, a hospital cannot only provide care that's high in quality. It must also deliver value and advance equality. Our index is designed to help them do just that."

The Texas Medical Center's Memorial Hermann Hospital ranked as No. 9 on the list that evaluated over 3,000 hospitals in the country. The hospitals are also given a grade on each of the three categories. Memorial Hermann received an A for civic leadership, an A- for value of care, and an A+ for patient outcomes — for an overall A+ grade.

Based on ranking, the Houston area's top 10 hospitals, which all received an overall grade of A- or above, are:

  1. Memorial Hermann Texas Medical Center (No. 9 in the country; No. 3 in the state)
  2. Harris Health System (No. 23 in the country; No. 5 in the state)
  3. Memorial Hermann Northeast Hospital in Humble (No. 165 in the country; No. 15 in the state)
  4. Memorial Hermann Hospital System (No. 297 in the country; No. 17 in the state)
  5. Brazosport Regional Health System in Lake Jackson (No. 304 in the country; No. 18 in the state)
  6. The Woman's Hospital of Texas (No. 373 in the country; No. 25 in the state)
  7. Memorial Hermann Katy Hospital in Katy (No. 374 in the country; No. 26 in the state)
  8. Houston Methodist San Jacinto Hospital in Baytown (No. 627 in the country; No. 43 in the state)
  9. Memorial Hermann Sugar Land Hospital in Sugar Land (No. 648 in the country; No. 44 in the state)
  10. Memorial Hermann Memorial City Medical Center (No. 652 in the country; No. 45 in the state)

The Harris Health System ranked the highest in Houston for civic leadership, and the Memorial Hermann Memorial City Medical Center scored the highest in the region for patient outcomes.

There were three other Texas hospitals among the top 10 in the nation — JPS Health Network in Fort Worth ranked as No. 1, Seton Northwest Hospital in Austin ranked as No. 4, and Parkland Health and Hospital System in Dallas ranked as No. 10.

The point of the study, according to the release, is to hold hospitals accountable for more than just one factor of success.

"There are some very fine hospitals that feel forced to focus on profitable elective procedures to stay in business," says Saini in the release. "This can lead to business decisions that make them look good on outcomes like mortality, but at the expense of equity. The data show that gaps between a hospital's clinical results and its performance in the community are sometimes very wide, which can contribute to disparities in care and put certain communities at risk."

The study factored in data from a variety of sources, including the 100 percent Medicare claims datasets (MEDPAR and outpatient); Internal Revenue Service pulled from Community Benefit Insight database; Healthcare Cost Report Information System administered by the Centers for Medicare and Medicaid Services; Securities and Exchange Commission filings; public records; Bureau of Labor Statistics; and other databases, according to the release.

"No other hospital ranking provides a 360-degree view of hospital performance," says Shannon Brownlee, senior vice president at the Lown Institute, in the release. "Many of the best-known hospitals score highly on patient outcomes but poorly on civic leadership and value of care. Our data show that it's possible to do well in all three categories, because some hospitals are doing it. That means all the people in their communities are being served effectively and fairly."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.